Jafron BiomedicalLtd Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Fan Dong
Chief executive officer
CN¥3.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 14.3yrs |
| CEO ownership | 45.9% |
| Management average tenure | 2yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return
Dec 10
Jafron BiomedicalLtd (SZSE:300529) Seems To Use Debt Rather Sparingly
Nov 22Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%
Oct 21Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce
Oct 02Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Sep 09The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence
Aug 25Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40
May 28A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
May 24Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge
May 08Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture
May 02Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital
Apr 13Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 22Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce
Mar 04CEO
Fan Dong (54 yo)
14.3yrs
Tenure
CN¥3,741,000
Compensation
Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Board of Directors & GM | no data | CN¥3.74m | 45.86% CN¥ 10.7b | |
| Director & Financial Director | 1.7yrs | CN¥500.50k | 0.019% CN¥ 4.4m | |
| Deputy General Manager | no data | CN¥865.40k | 0.46% CN¥ 106.4m | |
| Deputy GM & Director | no data | CN¥2.65m | 2.76% CN¥ 641.4m | |
| Deputy General Manager | 4.6yrs | CN¥2.44m | 0.031% CN¥ 7.3m | |
| General Manager | 1.3yrs | CN¥510.40k | no data | |
| Board Secretary | 2.3yrs | CN¥455.20k | 0.00044% CN¥ 102.4k |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: 300529's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Board of Directors & GM | 14.3yrs | CN¥3.74m | 45.86% CN¥ 10.7b | |
| Director & Financial Director | less than a year | CN¥500.50k | 0.019% CN¥ 4.4m | |
| Deputy GM & Director | 14.3yrs | CN¥2.65m | 2.76% CN¥ 641.4m | |
| Member of Global Advisory Board | 3.5yrs | no data | no data | |
| Non-Independent Director | 4.7yrs | CN¥1.08m | 0.099% CN¥ 23.0m | |
| Chairman of Supervisory Board | 4.7yrs | no data | no data | |
| Non-Independent Director | 4.7yrs | CN¥177.20k | no data | |
| Member of Global Advisory Board | 3.5yrs | no data | no data | |
| Member of Global Advisory Board | 3.5yrs | no data | no data | |
| Member of Global Advisory Board | 3.5yrs | no data | no data | |
| Member of Global Advisory Board | 3.5yrs | no data | no data | |
| Member of Global Advisory Board | 3.5yrs | no data | no data |
3.5yrs
Average Tenure
54yo
Average Age
Experienced Board: 300529's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 08:57 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jafron Biomedical Co.,Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Shuo Song | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |